Inclusion Criteria:

          -  Patients must have histological confirmation of breast carcinoma

          -  Patients must have invasive breast cancer (IBC), confirmed according to international
             consensus criteria:

               -  Onset: Rapid onset of breast erythema, edema, and/or peau d'orange, and/or warm
                  breast, with or without an underlying breast mass

               -  Duration: History of such findings no more than 6 months

               -  Extent: Erythema occupying at least 1/3 of whole breast

               -  Pathology: Pathologic confirmation of invasive carcinoma

          -  Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of
             0-1

          -  Patients must have negative HER2 expression on immunohistochemistry (IHC) (defined as
             0 or 1+) or fluorescence in situ hybridization (FISH) analysis; if HER2 is 2+,
             negative HER2 expression must be confirmed by FISH (HER2/cep17 ration < 2, and/or copy
             number less than 6); ER and PgR expression should be less than 10%

          -  Patients have left ventricular ejection fraction (LVEF) >= 50% by multigated
             acquisition scan (MUGA) or echocardiogram before study randomization

          -  Absolute neutrophil count (ANC) >= 1.5 x 10^9/L

          -  Platelet count >= 100 x 10^9/L

          -  Hemoglobin >= 9.0 g/dL

          -  Aspartate aminotransferase (AST) =< 3.0 x upper limit of normal (ULN)

          -  Alanine aminotransferase (ALT) =< 3.0 x ULN

          -  Alkaline phosphatase (ALP) =< 2.5 x ULN

          -  Total bilirubin =< 1.5 x ULN

          -  Creatinine (Cr) =< 1.5 mg/dL x ULN

          -  Creatinine clearance (CrCl) >= 50 mL/min calculated by the Cockroft-Gault

          -  Patients have the ability and willingness to sign written informed consent

          -  Patients of childbearing potential (women who are postmenopausal for < 1 year, not
             surgically sterilized, or not abstinent), have a negative urine pregnancy test, and
             agree to the consistent and correct use of one of the following acceptable methods of
             birth control: male partner who is sterile before the female subject's entry into the
             study and is the sole sexual partner for that female subject; intrauterine device,
             oral contraception, or barrier methods, including diaphragm or condom with a
             spermicide

        Exclusion Criteria:

          -  Stage IV disease, if the metastatic sites are not amendable for local therapy (i.e.
             radiation and/or surgery), and are not candidates for breast surgery will not be
             eligible

          -  History of radiotherapy for current breast cancer diagnosis

          -  History of recent malignancies < 5 years (except for cured non-melanomatous skin
             cancer or cured cervical carcinoma in situ)

          -  Known positive test(s) for human immunodeficiency virus infection, hepatitis C virus,
             acute or chronic active hepatitis B infection

          -  History of extensive interstitial lung disease, e.g., pneumonitis or pulmonary
             fibrosis or any evidence of extensive interstitial lung disease on baseline chest
             computed tomography (CT) scan

          -  Other known other significant medical or psychiatric condition that would make
             assessment of toxicity or efficacy difficult

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations that would limit compliance with
             study requirements

          -  Patients with a peripheral neuropathy > grade 1

          -  Patients with a history of New York Heart Association class 3 or 4 heart failure, or
             history of myocardial infarction, unstable angina, or cerebrovascular accident (CVA)
             within 6 months of protocol registration

          -  Patients have a history of prior therapy with carboplatin

          -  Patients have received a cumulative dose of doxorubicin of greater than 360 mg/m^2 or
             epirubicin of greater than 640 mg/m^2

          -  Patients have had prior radiotherapy for primary breast carcinoma or axillary lymph
             nodes

          -  Patients have history of diagnosed interstitial lung disease